Hyperthermia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line

Cancer

Volumn 115, Issue 2, 2009, Pages 311-323

  Cho, Jung Ah ^a,b   Park, Ho ^a   Kim, Hee Kyung ^a   Lim, Eun Hye ^a   Seo, Sang Won ^a   Choi, Joong Sub ^a   Lee, Kyo Won ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Hyperthermia; Mesenchymal stem cells; Tumor microenvironment; Tumor stroma

Indexed keywords

ANGIOGENIN; CHEMOKINE; CYTOKINE; MESSENGER RNA; NEUROTROPHIN 3; SOMATOMEDIN BINDING PROTEIN 4; TUMOR ANTIGEN;

ADIPOSE TISSUE; AMNION FLUID; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; SUPERNATANT; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

CELL CULTURE TECHNIQUES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; CYTOKINES; DISEASE PROGRESSION; HOT TEMPERATURE; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASM PROTEINS; STROMAL CELLS;

EID: 59449104379     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24032     Document Type: Article

References (51)

1. Musina RA, Bekchanova ES, Belyavskii AV, et al. Differentiation potential of mesenchymal stem cells of different origin. Bull Exp Biol Med. 2006;141:147-151.
2. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739-2749.
3. Schaffler A, Buchler C. Concise review: adipose tissuederived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells. 2007;25:818-827.
4. 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004;22:1338-1345.
5. Prockop DJ, Sekiya I, Colter DC. Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy. 2001;3:393-396.
6. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91:1017-1026.
7. Sasaki M, Abe R, Fujita Y, et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol. 2008;180:2581-2587.
8. Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008;15:730-738.
9. Peroni D, Scambi I, Pasini A, et al. Stem molecular signature of adipose-derived stromal cells. Exp Cell Res. 2008;314:603-615.
10. Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2006;80:267-274.
11. Hung SC, Deng WP, Yang WK, et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res. 2005;11: 7749-7756.
12. Franz M, Richter P, Geyer C, et al. Mesenchymal cells contribute to the synthesis and deposition of the laminin-5 gamma2 chain in the invasive front of oral squamous cell carcinoma. J Mol Histol. 2007;38:183-190.
13. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557-563.
14. Ohno S, Tachibana M, Fujii T, et al. Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int JCancer. 2002;97:770-774.
15. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003;2:14.
16. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia. 2001;17:1-18.
17. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3: 487-497.
18. Jones EL, Samulski TV, Dewhirst MW, et al. A pilot phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer. 2003;98:277-282.
19. Ben-Yosef R, Vigler N, Inbar M, et al. Hyperthermia combined with radiation therapy in the treatment of local recurrent breast cancer. Isr Med Assoc J. 2004;6:392-395.
20. Harima Y, Nagata K, Harima K, et al. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer. 2000;88:132-138.
21. Overgaard J. Effect of hyperthermia on malignant cells in vivo. A review and a hypothesis. Cancer. 1977;39:2637-2646.
22. Gnant MF, Turner EM, Alexander HR Jr. Effects of hyperthermia and tumour necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells. Cytokine. 2000;12:339-347.
23. Kanamori S, Nishimura Y, Okuno Y, et al. Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor. Int J Hyperthermia. 1999;15:267-278.
24. Song CW, Park HJ, Lee CK, et al. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia. 2005;21:761-767.
25. Engin K. Biological rationale and clinical experience with hyperthermia. Control Clin Trials. 1996;17:316-342.
26. Raposio E, Guida C, Baldelli I, et al. Characterization and induction of human pre-adipocytes. Toxicol In Vitro. 2007;21:330-334.
27. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211-228.
28. Tsai MS, Lee JL, Chang YJ, et al. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel 2-stage culture protocol. Hum Reprod. 2004;19:1450-1456.
29. Jones EA, Kinsey SE, English A, et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 2002;46:3349-3360.
30. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
31. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593-1603.
32. Kucerova L, Altanerova V, Matuskova M, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67:6304-6313.
33. Rowley DR. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. 1998;17:411-419.
34. Menon LG, Picinich S, Koneru R, et al. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells. 2007;25:520-528.
35. Mizuuchi H, Yoshiga K, Sakurai K, et al. Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-asci- tes tumor in vivo. Anticancer Res. 1996;16:381-387.
36. Saga T, Sakahara H, Nakamoto Y, et al. Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur J Cancer. 2001;37:1429-1434.
37. Shah SA. Participation of the immune system in regression of a rat Mc7 sarcoma by hyperthermia. Cancer Res. 1981;41:1742-1747.
38. Garrod DR. Cell to cell and cell to matrix adhesion. BMJ. 1993;306:703-705.
39. Grove M, Demyanenko G, Echarri A, et al. ABI2-deficient mice exhibit defective cell migration, aberrant dendritic spine morphogenesis, and deficits in learning and memory. Mol Cell Biol. 2004;24:10905-10922.
40. Wang C, Navab R, Iakovlev V, et al. Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. MolCancer Res. 2007;5:1031-1039.
41. Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs. 2006;17:1041-1044.
42. D'Sa-Eipper C, Chinnadurai G. Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities. Oncogene. 1998;16:3105-3114.
43. Shimoyama S, Gansauge F, Gansauge S, et al. Increased angiogenin expression in obstructive chronic pancreatitis surrounding pancreatic cancer but not in pure chronic pancreatitis. Pancreas. 1999;18:225-230.
44. Gho YS, Lee JE, Oh KS, et al. Development of antiangiogenin peptide using a phage-displayed peptide library. Cancer Res. 1997;57:3733-3740.
45. Durai R, Yang SY, Seifalian AM, et al. Role of insulin-like growth factor binding protein-4 in prevention of colon cancer. World J Surg Oncol. 2007;5:128.
46. Wang T, Xie K, Lu B. Neurotrophins promote maturation of developing neuromuscular synapses. J Neurosci. 1995;15:4796-4805.
47. Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. JLeukoc Biol. 2005;78:14-26.
48. Lindhout E, Vissers JL, Hartgers FC, et al. The dendritic cell-specific CC-chemokine DC-CK1 is expressed by germinal center dendritic cells and attracts CD38-negative mantle zone B lymphocytes. J Immunol. 2001;166:3284-3289.
49. Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy. 2003;5:362-369.
50. Siegel N, Rosner M, Hanneder M, Freilinger A, Hengstschlager M. Human amniotic fluid stem cells: a new perspective. Amino Acids. 2007;35:291-293.
51. Vincent T, Mechti N. Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma. 2005;46:803-811.